Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Raises Target Price to $16
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Indivior (GB:INDV), Vor Biopharma (VOR) and Allogene Therapeutics (ALLO)
Stifel Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $18.98
Indivior Analyst Ratings
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $16
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $15
Piper Sandler Remains a Buy on Indivior (INDV)
Deutsche Bank Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $16.34
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Northland Securities Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $25
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $22
Stifel Initiates Indivior(INDV.US) With Buy Rating, Announces Target Price $28.48
No Data
No Data